| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |